Concerns rise among Korean drug makers

Published: 2009-11-09 06:59:00

Updated: 2009-11-09 06:59:00

The domestic pharmaceutical sector is expected to face an inevitable blow under the government’s scheme to cut drug prices as part of its efforts to stamp out illegal rebate provisions.

Prospects have been grim for Korean firms, as they are getting pressed by multinationals' increasing market ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK